New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...
Targeted Oncology

Combining Axatilimab and Ruxolitinib to Minimize Steroid Use in cGVHD

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...
Fred Hutch

How chronic graft-versus-host disease unfolds ten years after transplant

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
European Medical Journal

Novel Conditioning Regimen Improves Sickle Cell Transplant Outcomes

Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...
Healio

Many patients disagree with clinicians’ assessments of their graft-versus-host disease

Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.
Applied Clinical Trials Online

FDA Clears Investigational New Drug Application for Phase Ib/IIa Trial of CK0802 in Steroid-Refractory Graft-Versus-Host Disease

On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...